BridgeBio Pharma (BBIO) Convertible Debt (2020 - 2025)

BridgeBio Pharma's Convertible Debt history runs 6 years deep, the most recent figure standing at $546.1 million for Q2 2025.

• In Q2 2025, Convertible Debt fell 25.99% year-over-year to $546.1 million; the TTM figure through Jun 2025 stood at $546.1 million (down 25.99% YoY), while the FY2024 annual figure was $738.9 million, up 35.98% from the prior year.
• Convertible Debt came in at $546.1 million for Q2 2025 at BridgeBio Pharma, roughly flat from $545.6 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $738.9 million in Q4 2024 to a low of $539.9 million in Q4 2021.
• A 5-year average of $639.0 million and a median of $638.9 million in 2021 frame the typical range for Convertible Debt.
• Across the five-year window, Convertible Debt surged 98.35% in 2021 and declined 26.16% in 2022, its largest moves.
• BridgeBio Pharma's Convertible Debt stood at $539.9 million in 2021, then jumped by 36.13% to $735.0 million in 2022, then dropped by 26.07% to $543.4 million in 2023, then surged by 35.98% to $738.9 million in 2024, then declined by 26.09% to $546.1 million in 2025.
• According to Business Quant data, Convertible Debt over the past three periods registered $546.1 million, $545.6 million, and $738.9 million for Q2 2025, Q1 2025, and Q4 2024 respectively.

Peer Comparison